Would you provide the KEYNOTE-522 regimen for a patient with ER low, PR+, HER2- stage IIIb breast cancer?

I think it is reasonable to use the KEYNOTE-522 regimen for a patient with stage IIIB breast can with a tumor that is ER-low (<10%), PR+ and HER2-negative, but with many caveats. Both biological and clinical outcomes data suggest that such cases are closer to HR-negative (as is ER-/PR+ disease). (1,...